As Vertex Pharmaceuticals INC (VRTX) Stock Rose, Shareholder Pointstate Capital LP Has Lowered Its Stake by $80.16 Million

March 14, 2018 - By Richard Conner

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.11, from 1.51 in 2017Q2. It is positive, as 32 investors sold VRTX shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Smithfield reported 890 shares or 0.02% of all its holdings. Balyasny Asset Mngmt Ltd Liability Com invested in 191,630 shares. Cambridge Research owns 7,625 shares. The New York-based Neuberger Berman Gp Lc has invested 0.04% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ontario – Canada-based Td Asset Mgmt has invested 0.1% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Gotham Asset Limited Liability Co holds 0.25% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 110,500 shares. Ghost Tree Lc holds 1.61% or 50,000 shares. Oakbrook Limited Liability Corp invested 0.2% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bancshares Of Ny Mellon has invested 0.08% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Legal & General Gru Public Limited holds 0.13% or 1.18M shares. 121,013 are held by Profund Advisors Lc. Advantus Capital Management invested in 25,555 shares or 0.1% of the stock. Enterprise Financial Services has invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 1832 Asset Mgmt Lp has invested 0.46% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Raymond James Svcs Advisors Inc holds 28,356 shares or 0.03% of its portfolio.

Since October 2, 2017, it had 0 insider buys, and 46 selling transactions for $123.56 million activity. Sachdev Amit also sold $2.56 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. 2,125 shares were sold by Arbuckle Stuart A, worth $336,345 on Tuesday, January 16. $616,465 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Chodakewitz Jeffrey. $544,730 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Silva Paul M on Tuesday, February 20. $1.70M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by MCGLYNN MARGARET G on Friday, March 2. 125,000 shares were sold by LEIDEN JEFFREY M, worth $17.67M on Monday, December 11.

Pointstate Capital Lp decreased its stake in Vertex Pharmaceuticals Inc (VRTX) by 52.74% based on its latest 2017Q3 regulatory filing with the SEC. Pointstate Capital Lp sold 527,400 shares as the company’s stock rose 33.61% with the market. The hedge fund held 472,600 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $71.85M, down from 1.00 million at the end of the previous reported quarter. Pointstate Capital Lp who had been investing in Vertex Pharmaceuticals Inc for a number of months, seems to be less bullish one the $44.27 billion market cap company. The stock decreased 0.33% or $0.58 during the last trading session, reaching $174.38. About 1.03 million shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since March 14, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Pointstate Capital Lp, which manages about $10.76B and $11.77 billion US Long portfolio, upped its stake in Empresa Dist Y Comercial Nor (NYSE:EDN) by 437,676 shares to 452,550 shares, valued at $17.99M in 2017Q3, according to the filing. It also increased its holding in Nxp Semiconductors N V (NASDAQ:NXPI) by 563,178 shares in the quarter, for a total of 608,178 shares, and has risen its stake in Medicines Co (NASDAQ:MDCO).

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on April, 26. They expect $0.27 EPS, up 107.69 % or $0.14 from last year’s $0.13 per share. VRTX’s profit will be $68.55M for 161.46 P/E if the $0.27 EPS becomes a reality. After $0.32 actual EPS reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -15.63 % negative EPS growth.

More recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: which released: “Updating My Bullish Views On Vertex Pharmaceuticals” on February 15, 2018. Also published the news titled: “Vertex Pharma (VRTX) Names Reshma Kewalramani, MD, as Chief Medical Officer” on February 26, 2018.‘s news article titled: “Vertex Pharmaceuticals Scores an Important Win” with publication date: February 17, 2018 was also an interesting one.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 99 analyst reports since July 31, 2015 according to SRatingsIntel. On Wednesday, July 5 the stock rating was maintained by Cowen & Co with “Hold”. JMP Securities maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Tuesday, December 12. JMP Securities has “Buy” rating and $200.0 target. The firm earned “Buy” rating on Thursday, February 1 by Oppenheimer. The firm has “Buy” rating by Jefferies given on Wednesday, January 31. BMO Capital Markets maintained the stock with “Buy” rating in Monday, September 25 report. Citigroup maintained the stock with “Buy” rating in Wednesday, July 19 report. Cowen & Co maintained the stock with “Buy” rating in Tuesday, March 13 report. The firm earned “Buy” rating on Friday, September 29 by BTIG Research. The firm earned “Overweight” rating on Friday, October 2 by Morgan Stanley. The rating was upgraded by Needham on Friday, June 23 to “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: